

— OhioHealth is pleased to present our —

# Fall Lung Cancer Conference 2025



*You are invited*

**Saturday, September 27, 2025  
7:30 AM to 2:30 PM**

OhioHealth David P. Blom Administrative Campus  
3430 OhioHealth Pkwy | Columbus, OH 43202

**Register today at [OhioHealth 2025 Fall Lung Cancer Conference](#)**

Registration is required for all categories. Please register by September 15.

OhioHealth Physician	\$100.00	Non-Physician Associate	\$50.00
External Physician	\$150.00	Resident/Fellow/Student	\$0.00

## CONFERENCE OBJECTIVES

*After participating in this activity, participants will be able to:*

- + Review data that supports lung cancer screening and how lung cancer screening can be implemented in a Health system.
- + Optimally select patients for neoadjuvant therapy for early-stage lung cancer.
- + Review evolving radiation therapy strategies for patients with stage III NSCLC in the era of immunotherapy.
- + Recognize treatment selection strategies for the first-line treatment of marker negative advanced stage NSCLC.
- + Discuss first line treatment options for stage IV NSCLC with common EGFR mutations.

# AGENDA

7–7:30 AM	<b>Registration</b>
7:30–8:15 AM	<b>Breakfast and Networking</b>
8:15–8:30 AM	<b>Welcome and House Keeping Announcements</b> <i>George Simon, MD; Vice President of Oncology, OhioHealth</i>
8:30–9:05 AM	<b>Lung Cancer Screening: Where are we now and where are we headed?</b> <i>Lary Robinson, MD, Thoracic Surgery, Moffitt Cancer Center, Tampa, FL</i>
9:05–9:15 AM	<b>Q &amp; A</b>
9:15–9:50 AM	<b>Neo-adjuvant Vs Adjuvant Therapy: Patient Selection from a Thoracic Surgery Viewpoint</b> <i>Vincent Daniel, MD; Thoracic Surgical Oncology, OhioHealth</i>
9:50–10 AM	<b>Q &amp; A</b>
10–10:20 AM	<b>Coffee Break and Networking</b>
10:20–10:55 AM	<b>Radiation therapy for NSCLC in the era of Immunotherapy. Need for a Paradigm Shift?</b> <i>Walter Curran, MD, Radiation Oncology, Piedmont Health System, Atlanta, GA</i>
10:55–11:05 PM	<b>Q &amp; A</b>
11:05–11:40 AM	<b>Treatment Selection strategies in driver mutation negative Advanced NSCLC?</b> <i>George Simon; Vice President of Oncology, OhioHealth</i>
11:40–11:50 PM	<b>Q &amp; A</b>
11:50 AM–12:25 PM	<b>How do you choose Anti-EGFR Therapy in Advanced Stage NSCLC in patients with Common EGFR mutations, in 2025?</b> <i>Shirish Gadgeel, MD, Henry Ford Cancer Center, Detroit MI</i>
12:25–12:35 PM	<b>Q &amp; A</b>
12–1:15 PM	<b>Lunch &amp; Networking</b>
1:15–2:15 PM	<b>Case Based Discussion</b> <b>Moderator:</b> <i>George R. Simon, MD</i> <b>Panelists:</b> <i>Vincent Daniel, MD; Lary Robinson, MD; Walter Curran, MD, Vijay Kudithipudi, MD; Sana Rehman, MD; Erin Bertino, MD; Shirish Gadgeel, MD</i>

## GENERAL INFORMATION

### Accreditation

OhioHealth is accredited by the Ohio State Medical Association (OSMA) to provide continuing medical education to physicians. OhioHealth designates this live activity for a maximum of **4.50 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OhioHealth Doctors Hospital is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. OhioHealth Doctors Hospital designates this program for a maximum of **4.50 AOA Category 1-B credits** and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.

**Nursing contact hours will be provided.** For any Nursing Continuing Professional Development (NCPD) questions or information, please contact Colleen Duncan at Colleen.Duncan@OhioHealth.com. OhioHealth is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. (P-086)

### American Board of Surgery

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's

Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

### Cancellation Policy

OhioHealth reserves the right to cancel or delay this event due to unforeseen circumstances.

### Disclosure

As an accredited CME provider, OhioHealth must ensure balance, independence, objectivity, and scientific rigor in all educational activities we sponsor. Faculty and planners participating in sponsored activities must disclose all financial relationships. Any potential conflicts of interest will be mitigated and revealed prior to the start of the education.

### Additional Information

This conference is planned and presented by OhioHealth's American College of Surgeons Commission on Cancer accredited hospitals: OhioHealth Riverside Methodist Hospital, OhioHealth Grant Medical Center, OhioHealth Doctors Hospital, OhioHealth Grady Memorial Hospital, OhioHealth Mansfield Hospital, OhioHealth Dublin Methodist Hospital, OhioHealth Marion General Hospital and OhioHealth O'Bleness Hospital.



### **George Simon, MD, FACP, FCCP**

**Vice President of Oncology, OhioHealth**

Dr. Simon currently serves as VP of Oncology at OhioHealth, one of Ohio's largest health systems. In this role, Dr. Simon oversees OhioHealth's comprehensive oncology program and drives efforts to expand access to high-quality care and research for patients across the region.

Prior to joining OhioHealth, Dr. Simon served in leadership roles at some of the nation's top cancer institutions, including the University of Texas MD Anderson Cancer Center, Houston TX and the H Lee Moffitt Cancer Center, Tampa, FL

Dr. Simon's research interests include individualizing therapy based on a patient's molecular profile (precision medicine), early drug development, and artificial intelligence-based predictive strategies.

Some of his research has been funded by the National Cancer Institute (R21, R01), the Department of Defense, and other institutional funding mechanisms. Dr. Simon was also part of a team of physicians who competed successfully for a Lung Cancer SPORE (Specialized Programs of Research Excellence), a multi-investigator NCI grant. The research efforts have led to two United States Patents.

Nationally, Dr. Simon served as a reviewer for several panels of the National Cancer Institute, Department of Defense and currently chairs an Onc study section of the Veterans Administration Merit Review board. He also served as a member of American College of Chest Physicians and National Comprehensive Cancer Network (NCCN) Lung Cancer guidelines panels. Internationally, Dr. Simon have also served as reviewer for granting organizations in UK, Ireland and Australia.

Throughout his career, Dr. Simon has strived to make an impact in the field of cancer through patient care, education, research, and innovation.

## OUR SPEAKERS



### **Walter John Curran, Jr., MD**

#### **Chief of Piedmont Oncology Institute for Piedmont Healthcare**

For the past several decades, Walter J. Curran Jr., M.D. has focused on oncology patient care and conducting clinical and translational cancer research at the institutional level, national cooperative or network group level, and the global level. He has specialized in adult patients who have been diagnosed with either a brain tumor or lung cancer.

Previously, he served as executive director of Winship Cancer Institute (Winship) from 2009 to 2021, successfully leading Winship to align its cancer care and cancer prevention efforts with its research and education programs. His work lessened the cancer burden across the state of Georgia. Winship was approved as the latest NCI-designated comprehensive cancer center effective April 1, 2017. Dr. Curran also served as one of the founding leaders of NRG Oncology, which began its involvement as one of four adult NCI-supported National Clinical Trials Network groups in 2014. As NRG Oncology group chair, he integrated the outstanding science of cancer investigators with the national and international reach of a large NCI-supported network group.

In January 2024, Dr. Curran joined Piedmont as the inaugural chief of Piedmont Oncology Institute. As of February 2025, Dr. Curran is the Whitaker Endowed Chief of Piedmont Oncology. He is committed to transforming cancer care and leading Piedmont Oncology as one of the nation's premier community-based programs providing care that is fully aligned with discovery and innovation.



### **Vincent C. Daniel, MD**

#### **Thoracic Surgeon, OhioHealth Grant Medical Center, Columbus, OH**

Dr. Daniel is a thoracic surgeon specializing in the treatment of lung and esophageal cancers, mediastinal tumors and other diseases arising in the chest. His specific area of expertise is in robotic-assisted surgery, as well as in other types of minimally invasive procedures for the surgical treatment of these diseases. Dr. Daniel uses advanced, minimally invasive technology that includes VATS (video-assisted thoracic surgery) and RATS (robotic-assisted thoracic surgery). His expertise additionally includes cutting-edge treatment of thoracic malignancies. He also has significant experience in the treatment of rare types of tracheal diseases, such as tracheal stenosis, tracheal tumors and tracheomalacia. He is a member of the Society of Thoracic Surgeons and the American College of Surgeons. He has received multiple teaching, clinical and scientific awards and honors, and routinely serves as a reviewer of numerous scientific journals. Dr. Daniel is passionate about the implementation and benefits of robotic-assisted surgery in the treatment of thoracic cancers.

## OUR SPEAKERS




### **Shirish M Gadgeel, MD**

**Division Head for Hematology/Medical Oncology, Associate Director, Patient Experience and Clinical Care, Henry Ford Health**

After graduating with his MBBS medical degree from the University of Bombay in Mumbai, India, he completed his Internal Medicine residency in Mumbai. He also completed an internship at LaGuardia Hospital (now Long Island Jewish Forest Hills), as well as his Hematology/Oncology residency and Bone Marrow Transplantation Fellowship at Wayne State University. Following his fellowship, Dr. Gadgeel served as director of the Thoracic Oncology Program and co-leader of Molecular Therapeutics Program at Karmanos Cancer Institute.

His clinical research experience spans 20 years. He is also a member of the steering committee of the Lung Cancer Committee of Southwest Oncology Group. He is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals, including Clinical Cancer Research, Journal of Clinical Oncology, Lancet Oncology, and Journal of Thoracic Oncology. He has served as faculty for the annual meeting of the American Society of Clinical Oncology (ASCO) and as a member of the education committee of ASCO. He is a member of the Communications committee of the International Association of Study of Lung Cancer (IASLC). He was awarded by the National Cancer Institute the Cancer Clinical Investigator Team Leadership Award in 2012.



### **Lary Robinson, MD**

**Professor of Thoracic Surgery and Interdisciplinary Oncology, Moffitt Cancer Center**

Dr. Robinson, a native of Kansas, received his undergraduate B.A. degree in anthropology at the University of Kansas and his medical degree from the Washington University School of Medicine in St. Louis, Missouri. He completed his internship and residency in general and cardiothoracic surgery at the Duke University Medical Center. Additionally, he completed a fellowship in cardiac research and clinical cardiac surgery at the St. Thomas' Hospital in London. He also served as a Flight Surgeon at the rank of Major, USAF in Thailand during the Vietnam War. Dr. Robinson then came to the University of South Florida College of Medicine in Tampa in 1994 where he is currently a Professor of Surgery (Thoracic) and Interdisciplinary Oncology.

He practices thoracic oncology at the Moffitt Cancer Center as a Senior Member with Tenure of the Moffitt Medical Group. He is Director, Lung Cancer Early Detection (LEAD) Center at Moffitt which includes the Lung Cancer Screening Program, Lung Nodule Clinic and Lung Surveillance Clinic. Dr. Robinson is the author or co-author of over 180 medical publications. He is Principal Investigator on research protocols involving risk factors for developing lung cancer in never-smoking women, the use of biomarkers for early lung cancer diagnosis, nutritional prehabilitation to improve immunotherapy response in advanced lung cancer, and a clinical study evaluating the influence of nutrition and the gut microbiome on the effectiveness of immunotherapy.